NSC348884

Research use only, not for human use.

NSC348884 is a nucleophosmin inhibitor disrupts oligomer formation and induces apoptosis, inhibits cell proliferation at an IC50 of 1.7-4.0 μM in distinct cancer cell lines.

NSC348884 is a nucleophosmin inhibitor. NSC348884 also disrupts oligomer formation and induces apoptosis in human cancer cells.

NSC348884 (0-6 μM; 24 h) binds with NPM and disrupts NPM oligomer formation.NSC348884 (0.01-100 μM; 4 d) shows cytotoxicity to cancer cells.NSC348884 (1 μM; 4 d) shows cytotoxicity to mantle cell lymphoma with 0.1 nM doxorubicin.NSC348884 (1-5 μM; 24 h) induces cell apoptosis.NSC348884 (0-5 μM; 0-24 h) upregulates the concentration of p53.Cell Viability Assay Cell Line:LNCaP and Granta cell lines Concentration:0.01-100 μM Incubation Time:4 days Result:Inhibited LNCaP cells and Granta cell lines with IC50s of 4 and 1.7 μM, respectively.Apoptosis Analysis Cell Line:LNCaP cell line Concentration:1-5 μM Incubation Time:24 h Result:Induced apoptosis in LNCaP cell line.Western Blot Analysis Cell Line:LNCaP cell line Concentration:0-5 μM Incubation Time:0-24 h Result:Dose-dependently increased both p53 protein level and phosphorylation on Ser15, and increased the concentration of p21.Western Blot Analysis Cell Line:SKOV3, ES2 and MOSEC/Luc cell linesConcentration:0, 2.5 and 5 μM Incubation Time:48 h Result:Increased PD-L1 expression in ovarian cancer cells.

NSC348884 (50 μg; i.p. once) reduces tumor growth. Animal Model:C57Bl/6J mice with MOSEC/Luc cells injection Dosage:50 μg Administration:Intraperitoneal injection; 50 μg once Result:Reduced tumorigenesis, but not completely inhibited.

NSC348884 | NSC 348884 | NSC-348884

Others

Other Targets

nucleophosmin

Cancer

——

81624-55-7

636.81

C38H40N10

>98% (HPLC)

DMSO : ≥ 34 mg/mL; 53.39 mM

Cc1cc2c(cc1)nc(CN(CCN(Cc1nc3c([nH]1)cc(C)cc3)Cc1nc3c([nH]1)cc(C)cc3)Cc1nc3c([nH]1)cc(C)cc3)[nH]2

N,N,N',N'-tetrakis[(6-methyl-1H-benzimidazol-2-yl)methyl]ethane-1,2-diamine

(-20℃)

With Ice Pack

≥ 2 years